Sai Life Sciences Limited, an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Centre at its integrated R&D Campus in Hyderabad.
Announcing the launch, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center reflects this commitment, designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics.”
The Peptide Research Centre is designed to support innovator pharma and biotech companies with specialised services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.
Maneesh Pingle, Head of Discovery Services, said: “The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects."
The new Peptide Research Centre will be integrated with Sai Life Sciences’ end-to-end discovery services, spanning synthetic and medicinal chemistry, biology, DMPK, and toxicology. This holistic approach ensures seamless transitions across different stages of drug discovery, accelerating timelines and enhancing success rates for peptide-based drug development.
